Citation Impact
Citing Papers
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
2005
Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology
2009
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Untangling the ErbB signalling network
2001 Standout
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
2001
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
1997
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
1995
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
The relationship between prognostic and predictive factors in the management of breast cancer
1998
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
EGFR Antagonists in Cancer Treatment
2008 Standout
p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study
2006
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance
2000
Histologically Based Methods for Detection of Mucin
2000
Breast cancer
2016 Standout
Ferroptosis as a p53-mediated activity during tumour suppression
2015 StandoutNature
Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression ☆ ☆This study was supported by the National Natural Science Foundation of China (No. 39870753) and Changhai Hospital ‘123’ Project.
2001
Molecular mechanisms of epithelial–mesenchymal transition
2014 Standout
Epidermal growth factor-related peptides and their receptors in human malignancies
1995 Standout
Ovarian cancer
2014 Standout
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Head and neck cancer
2008 Standout
Renal-Cell Carcinoma
1996 Standout
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
The Hedgehog and Wnt signalling pathways in cancer
2001 StandoutNature
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
2005
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
<i>TP53</i> Status and Response to Chemotherapy in Breast Cancer
2008
Blinded by the Light: The Growing Complexity of p53
2009 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
2010 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma
1995
p16(MTS-1/CDKN2/INK4a) in Cancer Progression
2001
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Apoptosis
2002 Standout
Genetic alterations in breast cancer
1995
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
2015
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
2014 Standout
Neuroblastoma
2007 Standout
Synthetic lethality: the road to novel therapies for breast cancer
2016
Cell Polarity in Motion: Redefining Mammary Tissue Organization Through EMT and Cell Polarity Transitions
2010
Clinical implications of p53 mutations
1999
Primary brain tumours in adults
2012 Standout
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
2008
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
2000
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival
1993
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)
1999
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
2006 Standout
The mutant p53 mouse as a pre-clinical model
2013
β-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds
2002 Standout
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
2012
Proliferation of aneuploid human cells is limited by a p53-dependent mechanism
2010
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
1998
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
2003
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
Linking gene expression patterns to therapeutic groups in breast cancer.
2000
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
2009 Standout
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer
2002
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
A Potent Glucose–Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells
2016
Metabolic reprogramming and cancer progression
2020 StandoutScience
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
2001
Real-Time PCR Technology for Cancer Diagnostics
2002
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
2003
Works of E. Berns being referenced
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
1998
Allelotype of 28 human breast cancer cell lines and xenografts
2003
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)
2010
Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay
1992
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
2012
Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer
1995
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)
2006
A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.
1997
Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours
1996
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
2011
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
1992
Prognostic factors and response to therapy in breast cancer.
1993
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
2000
Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors.
1992